Iris Dorbian

Cupertino, California-based Corinth MedTech, a urology healthcare company, has secured $12 million in financing. ShangBay Capital LLC and Aethan Capital Inc led the round.

Alma, a New York-based co-practicing community of therapists, coaches, and wellness professionals, raised $8 million in Series A funding, according to a Medium blog post. Tusk Venture Partners led the round with participation from Sound Ventures, First Round Capital, Primary Ventures, Box Group and able Partners.

San Francisco and London-based MakerSights, a product decision engine for retail, has secured $8.5 million in Series A funding. The investors included Forerunner Ventures. In addition to the funding, Brian O’Malley of Forerunner Ventures will join the MakerSights' board of directors.

Carslbad, California-based Acutus Medical, an arrhythmia care company, has secured $100 million in Series D funding and a $70 million credit facility. The Series D investors included 8VC, Opaleye Management, Pura Vida Investments, OrbiMed, Deerfield Management Company, Advent Venture Partners, Xeraya Capital and GE Ventures. OrbiMed Credit and Royalties Fund and Deerfield Management provided the credit facility.

Jumpspeed Ventures, an Israeli venture firm, has closed its new fund at $17.7 million, according to an announcement on the site. Jumpspeed invests in early-stage startups based in Jerusalem.

Redwood City, California-based Codexis, a synthetic biology company, has secured $50 million in funding. The investor was Casdin Capital LLC.

Xealth, a platform for connecting digital health, has secured $3 million in funding. The investors included Atrium Health, Cleveland Clinic, MemorialCare Innovation Fund, McKesson Ventures, Novartis, Philips, ResMed, Threshold Ventures, Providence Ventures, UPMC,  Froedtert and the Medical College of Wisconsin health network.

CoHive, a newly launched Indonesian co-working space company, has secured $13.5 million in financing. Stonebridge Ventures led the round.

Unily, a digital workplace platform, has secured $68 million in funding, according to an announcement on its site. The backers were Silversmith Capital Partners and Farview Equity Partners.

Akero Therapeutics Inc, a biotech firm, has raised about $92 million for its IPO after pricing its 5.75 million shares at $16 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol "AKRO." J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group L.L.C. are the lead underwriters. Akero's pre-IPO investors included Janus Henderson Investors, Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, LifeSci Venture Partners, Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures.